Microbial Drug Resistance

Microbial Drug Resistance (ISSN 1076-6294) is a monthly international peer-reviewed journal published by Mary Ann Liebert, Inc. in the United States, dedicated to advancing the understanding of antimicrobial resistance across a broad spectrum of pathogens, including bacteria, fungi, viruses, and parasites. The journal, which is indexed in the Science Citation Index (SCI), maintains a 2022 impact factor of 2.7 and is classified as a Zone 4 journal in the Chinese Academy of Sciences ranking for the medical sciences. It serves a diverse audience of researchers, clinicians, and public health professionals by publishing high-quality studies that bridge the gap between fundamental molecular biology and clinical application. Key areas of focus include the elucidation of resistance mechanisms, epidemiological surveillance, the development of novel antimicrobial agents, and strategies for controlling the spread of multidrug-resistant and pan-resistant organisms. While the journal is not open access and operates with a relatively concise review cycle, it remains a competitive venue that prioritizes submissions demonstrating significant innovation and clear clinical relevance, thereby ensuring that published work contributes meaningfully to the global effort to combat microbial resistance.